Asthma
Commentary
What to do when the evidence is not conclusive
Why don't we have conclusive evidence? Because the right studies have not been done.
Applied Evidence
When guideline treatment of asthma fails, consider a macrolide antibiotic
This class of drugs has the potential to benefit patients with persistent, poorly controlled asthma and those with new-onset disease as an adjunct...
Conference Coverage
Dupilumab effective in early- and late-onset asthma
NEW ORLEANS – Dupilumab may be more effective in reducing severe asthma exacerbations in patients with late-onset asthma.
Conference Coverage
Tips for helping children improve adherence to asthma treatment
NEW ORLEANS – Common patient-related barriers include poor understanding of how the medication may help and how to...
Feature
Wildfire smoke impact, part 2: Resources, advice for patients
What can doctors tell their patients with cardiovascular and pulmonary conditions about the risks of smoke from wildfires?
Conference Coverage
Mesh nebulizer worked faster to control acute asthma
MADRID – Relative to jet nebulizers, mesh devices achieve urgent asthma control in children more quickly.
Conference Coverage
Trial confirms as-needed inhalers suffice for mild to moderate asthma
MADRID – Yet another trial supports as-needed inhaled steroids for mild to moderate asthma.
From the Journals
Serum testosterone and estradiol levels associated with current asthma in women
The overall prevalence of current asthma in the sample was 9% (6% in men and 13% in women).
From the Journals
Step-up therapy with glucocorticoids benefits black children with asthma
Almost half of black children with poorly controlled asthma responded to higher doses of an inhaled glucocorticoid, compared with LABA, but this...
Feature
Wildfire smoke has acute cardiorespiratory impact, but long-term effects still under study
While research advances, the unforgiving wildfire season looms, assuring more destruction of property and threats to cardiorespiratory health.
News
FDA approves mepolizumab for severe eosinophilic asthma in younger kids
The biologic has been approved for patients aged 6 years and older in the European Union since August 2018.